Index S&P 500
P/E 65.08
EPS (ttm) 2.99
Insider Own 0.09%
Shs Outstand 1.77B
Perf Week -1.23%
Market Cap 343.71B
Forward P/E 16.07
EPS next Y 12.11
Insider Trans -21.27%
Shs Float 1.76B
Perf Month 2.32%
Income 5.30B
PEG 10.39
EPS next Q 2.95
Inst Own 73.63%
Short Float 1.14%
Perf Quarter 16.03%
Sales 55.00B
P/S 6.25
EPS this Y -2.11%
Inst Trans 0.10%
Short Ratio 3.85
Perf Half Y 7.56%
Book/sh 3.84
P/B 50.70
EPS next Y 11.36%
ROA 3.82%
Short Interest 20.19M
Perf Year 30.56%
Cash/sh 7.45
P/C 26.12
EPS next 5Y 6.26%
ROE 53.93%
52W Range 135.85 - 199.95
Perf YTD 25.57%
Dividend Est. 6.18 (3.18%)
P/FCF 19.37
EPS past 5Y -5.77%
ROI 8.17%
52W High -2.68%
Beta 0.61
Dividend TTM 6.13 (3.15%)
Quick Ratio 0.71
Sales past 5Y 11.76%
Gross Margin 69.31%
52W Low 43.24%
ATR (14) 3.67
Dividend Ex-Date Oct 15, 2024
Current Ratio 0.81
EPS Y/Y TTM -38.66%
Oper. Margin 31.96%
RSI (14) 54.08
Volatility 2.02% 1.54%
Employees 50000
Debt/Eq 10.42
Sales Y/Y TTM -1.83%
Profit Margin 9.63%
Recom 1.77
Target Price 198.13
Option/Short Yes / Yes
LT Debt/Eq 8.56
EPS Q/Q -32.44%
Payout 220.33%
Rel Volume 0.69
Prev Close 199.35
Sales Surprise 3.14%
EPS Surprise 3.29%
Sales Q/Q 4.31%
Earnings Jul 25 BMO
Avg Volume 5.24M
Price 194.59
SMA20 -0.52%
SMA50 5.42%
SMA200 14.32%
Trades
Volume 3,623,565
Change -2.39%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-05-24 Upgrade
HSBC Securities
Hold → Buy
$185
May-17-24 Initiated
Cantor Fitzgerald
Overweight
$200
Jan-29-24 Upgrade
William Blair
Mkt Perform → Outperform
Dec-18-23 Downgrade
HSBC Securities
Buy → Hold
Dec-11-23 Upgrade
Goldman
Neutral → Buy
Nov-09-23 Initiated
Deutsche Bank
Hold
$150
Oct-30-23 Upgrade
Barclays
Equal Weight → Overweight
$160 → $170
Oct-20-23 Resumed
UBS
Neutral
$157 → $150
Sep-29-23 Initiated
Raymond James
Outperform
$177
Jul-25-23 Initiated
William Blair
Mkt Perform
Jul-14-23 Initiated
HSBC Securities
Buy
$167
Apr-05-23 Downgrade
Argus
Buy → Hold
Mar-01-23 Initiated
Guggenheim
Buy
$172
Feb-22-23 Downgrade
Wolfe Research
Outperform → Peer Perform
Feb-10-23 Upgrade
SVB Securities
Underperform → Market Perform
$135 → $153
Nov-18-22 Initiated
Credit Suisse
Outperform
$170
Nov-08-22 Downgrade
Societe Generale
Buy → Hold
Aug-01-22 Downgrade
Atlantic Equities
Overweight → Neutral
$178 → $162
May-23-22 Initiated
SVB Leerink
Underperform
$140
May-06-22 Downgrade
Daiwa Securities
Outperform → Neutral
$150
Show Previous Ratings
Today 08:30AM
Sep-10-24 07:00AM
Sep-09-24 05:45PM
12:05PM
09:00AM
07:30AM
Loading…
Sep-08-24 07:30AM
03:56AM
Sep-06-24 10:13AM
Sep-05-24 04:50AM
Sep-04-24 09:15AM
08:00AM
07:00AM
Sep-03-24 11:32PM
05:45PM
09:17AM
08:00AM
Loading…
08:00AM
12:00AM
Sep-02-24 05:07PM
08:45AM
Sep-01-24 05:53AM
Aug-30-24 10:38AM
09:45AM
06:45AM
04:20AM
Aug-29-24 09:00AM
05:50AM
Aug-28-24 11:16AM
06:32AM
Aug-27-24 08:15AM
08:05AM
01:53PM
Loading…
Aug-26-24 01:53PM
05:46AM
Aug-25-24 06:30PM
Aug-23-24 08:04AM
Aug-20-24 09:44AM
08:00AM
04:33AM
(Pharmaceutical Technology)
Aug-19-24 02:05PM
Aug-18-24 05:50AM
03:19AM
Aug-17-24 03:58PM
10:00AM
Aug-15-24 05:30PM
09:13AM
09:00AM
07:49AM
Aug-13-24 07:03PM
07:03PM
Aug-12-24 05:30AM
(The Wall Street Journal)
Aug-11-24 03:35PM
Aug-10-24 06:50AM
Aug-09-24 04:01PM
09:00AM
06:57AM
Aug-08-24 01:02AM
Aug-07-24 07:01PM
08:00AM
(Investor's Business Daily)
Aug-06-24 08:00AM
Aug-05-24 05:56AM
Aug-02-24 04:32AM
(Pharmaceutical Technology)
Aug-01-24 02:00PM
11:41AM
08:23AM
Jul-31-24 08:00AM
Jul-30-24 09:00AM
08:00AM
Jul-29-24 01:37PM
06:30AM
(The Wall Street Journal)
Jul-28-24 08:05AM
Jul-26-24 04:32AM
(Pharmaceutical Technology)
03:21AM
(Thomson Reuters StreetEvents)
02:00AM
Jul-25-24 04:25PM
04:08PM
(Investor's Business Daily)
03:30PM
02:28PM
01:43PM
01:19PM
12:38PM
12:12PM
11:22AM
(The Wall Street Journal)
10:21AM
10:18AM
09:30AM
09:30AM
09:00AM
(Investor's Business Daily)
08:46AM
08:45AM
08:30AM
07:46AM
(Pharmaceutical Business Review)
07:45AM
07:42AM
(Associated Press Finance)
07:39AM
07:36AM
Jul-24-24 06:08PM
03:52AM
(Pharmaceutical Technology)
Jul-23-24 08:00AM
07:02AM
Jul-22-24 10:41AM
09:49AM
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hudson Thomas J Officer Aug 08 '24 Proposed Sale 189.08 49,170 9,297,210 Aug 08 05:40 PM GONZALEZ RICHARD A EXECUTIVE CHAIRMAN OF BOARD Aug 05 '24 Sale 186.52 66,500 12,403,580 446,599 Aug 07 05:00 PM Hudson Thomas J Officer Aug 07 '24 Proposed Sale 187.62 101,886 19,115,380 Aug 07 04:22 PM GONZALEZ RICHARD A Officer Aug 05 '24 Proposed Sale 187.36 66,500 12,459,360 Aug 05 10:54 AM GONZALEZ RICHARD A EXECUTIVE CHAIRMAN OF BOARD Jul 17 '24 Option Exercise 77.49 282,845 21,919,048 795,944 Jul 19 04:40 PM GONZALEZ RICHARD A EXECUTIVE CHAIRMAN OF BOARD Jul 17 '24 Sale 175.00 282,845 49,497,875 513,099 Jul 19 04:40 PM Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Mar 20 '24 Sale 176.30 21,082 3,716,757 55,903 Mar 22 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 18 '24 Option Exercise 61.36 26,110 1,602,110 119,890 Mar 20 05:00 PM Stewart Jeffrey Ryan EVP, CHIEF COMMERCIAL OFFICER Mar 18 '24 Sale 178.79 58,949 10,539,508 60,941 Mar 20 05:00 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 01 '24 Option Exercise 61.36 45,700 2,804,152 89,517 Mar 05 05:30 PM RICHMOND TIMOTHY J. EVP, CHIEF HR OFFICER Mar 01 '24 Sale 177.27 75,680 13,415,503 13,837 Mar 05 05:30 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Feb 23 '24 Option Exercise 61.36 14,140 867,630 41,205 Mar 01 05:50 PM Reents Scott T EVP, CHIEF FINANCIAL OFFICER Feb 23 '24 Sale 177.44 14,140 2,509,002 27,065 Mar 01 05:50 PM Buckbee Kevin K SVP, CONTROLLER Feb 29 '24 Sale 176.65 5,144 908,688 6,983 Mar 01 05:50 PM Michael Robert A. PRES & CHIEF OPERATING OFFICER Feb 29 '24 Option Exercise 58.30 21,560 1,257,012 167,524 Mar 01 05:50 PM Michael Robert A. PRES & CHIEF OPERATING OFFICER Feb 29 '24 Sale 176.45 68,879 12,153,957 98,645 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 29 '24 Sale 177.39 9,891 1,754,555 10,397 Mar 01 05:50 PM GONZALEZ RICHARD A CHAIRMAN OF THE BOARD AND CEO Feb 28 '24 Sale 177.27 138,616 24,572,458 519,099 Mar 01 05:50 PM Siatis Perry C EVP, GC AND SECRETARY Feb 23 '24 Option Exercise 137.36 13,753 1,889,115 41,926 Feb 27 05:10 PM Siatis Perry C EVP, GC AND SECRETARY Feb 23 '24 Sale 177.51 13,753 2,441,295 28,173 Feb 27 05:10 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Feb 21 '24 Option Exercise 58.88 52,870 3,112,986 296,814 Feb 23 05:00 PM SALEKI-GERHARDT AZITA EVP, CHIEF OPERATIONS OFFICER Feb 21 '24 Sale 173.71 52,870 9,184,048 243,944 Feb 23 05:00 PM Donoghoe Nicholas EVP, CHIEF BUS/STRAT OFFICER Dec 26 '23 Sale 154.72 2,912 450,545 55,903 Dec 28 05:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite